阴离子交换蛋白2与原发性胆汁性胆管炎发病机制的关系

鉏曦; 邢练军

doi:10.3969/j.issn.1001-5256.2021.03.044

阴离子交换蛋白2与原发性胆汁性胆管炎发病机制的关系

DOI: 10.3969/j.issn.1001-5256.2021.03.044

鉏曦,
邢练军^,

上海中医药大学附属龙华医院脾胃二科，上海 200000

基金项目:

上海市进一步加快中医药事业发展三年行动计划(2018年—2020年) (ZY〔2018-2020〕-CCCX-2002-03);

上海市申康临床创新项目-新兴前沿技术联合攻关项目 (SHDC12019118)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：鉏曦负责资料分析，撰写论文；邢练军负责指导撰写文章并帮助修改论文。

详细信息

作者简介:
鉏曦(1992—)，男，主要从事中西医防治肝病的研究

通信作者:
邢练军，xingdoctor@126.com

中图分类号: R575
计量
- 文章访问数: 387
- HTML全文浏览量: 86
- PDF下载量: 28
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-13
- 录用日期: 2020-11-16
- 出版日期: 2021-03-20

Role of anion exchanger 2 in the pathogenesis of primary biliary cholangitis

Xi CHU,
Lianjun XING^,

Second Department of Spleen and Stomach, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200000, China

摘要

摘要: 原发性胆汁性胆管炎(PBC)的致病原因和发病机制仍不明确。目前主要认为胆管微环境变化和自身免疫反应是其发病的主要因素。阴离子交换蛋白2(AE2)是一种位于上皮细胞细胞膜上的HCO₃^-/Cl^-交换蛋白，因发现其可以诱发和加重PBC的病程而被广大学者重视。从AE2以及相关调控机制着手，归纳总结了AE2在胆管微环境和自身免疫反应中所起到的作用，进一步对PBC的发病机制进行分析，以期通过探索AE2在PBC中的调控机制寻找到潜在的PBC治疗新方法以及诊断和预后判断指标。
- 原发性胆汁性胆管炎 /
- 反向转运物 /
- 病理过程
Abstract: The etiology and pathogenesis of primary biliary cholangitis (PBC) remain unclear at present, and it is believed that the change in bile duct microenvironment and autoimmune response are the main factors for the onset of this disease. Anion exchanger 2 (AE2) is an HCO₃^-/Cl^- exchange protein located on the membrane of epithelial cells and has been taken seriously by scholars since studies have shown that it can induce and aggravate PBC. This article summarizes the role of AE2 in bile duct microenvironment and autoimmune response from the aspects of AE2 and related regulatory mechanisms and further analyzes the pathogenesis of PBC, so as to find new therapies and diagnostic and prognostic indicators for PBC by exploring the regulatory mechanism of AE2 in PBC.
- Primary Biliary Cholangitis /
- Antiporters /
- Pathologic Processes

HTML全文

参考文献(32)

[1]	CHEN CW, CHENG J, DOU XG, et al. Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J]. J Clin Hepatol, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004 陈成伟, 成军, 窦晓光, 等. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004
[2]	ZENG N, DUAN W, CHEN S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: A systematic review and meta-analysis[J]. Hepatol Int, 2019, 13(6): 788-99. DOI: 10.1007/s12072-019-09984-x
[3]	LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69(1): 394-419.
[4]	RODRIGUES PM, PERUGORRIA MJ, SANTOS-LASO A, et al. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?[J]. J Hepatol, 2018, 69(6): 1371-1383. DOI: 10.1016/j.jhep.2018.08.020
[5]	TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, VERGANI D, et al. The challenges of primary biliary cholangitis: What is new and what needs to be done[J]. J Autoimmun, 2019, 105: 102328. DOI: 10.1016/j.jaut.2019.102328
[6]	ROMERO MF, CHEN AP, PARKER MD, et al. The SLC4 family of bicarbonate (HCO₃) transporters[J]. Mol Aspects Med, 2013, 34(2-3): 159-182. DOI: 10.1016/j.mam.2012.10.008
[7]	MEDINA JF. Role of the anion exchanger 2 in the pathogenesis and treatment of primary biliary cirrhosis[J]. Dig Dis, 2011, 29(1): 103-112. DOI: 10.1159/000324144
[8]	ARENAS F, HERVIAS I, URIZ M, et al. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells[J]. J Clin Invest, 2008, 118(2): 695-709.
[9]	CORPECHOT C, CARRAT F, BAHR A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis[J]. Gastroenterology, 2005, 128(2): 297-303. DOI: 10.1053/j.gastro.2004.11.009
[10]	KIM S, HAN SY, YU KS, et al. Impaired autophagy promotes bile acid-induced hepatic injury and accumulation of ubiquitinated proteins[J]. Biochem Biophys Res Commun, 2018, 495(1): 1541-1547. DOI: 10.1016/j.bbrc.2017.11.202
[11]	MARIN JJ, MACIAS RI, BRIZ O, et al. Bile acids in physiology, pathology and pharmacology[J]. Curr Drug Metab, 2015, 17(1): 4-29. DOI: 10.2174/1389200216666151103115454
[12]	BEUERS U, HOHENESTER S, DE BUY WENNIGER LJ, et al. The biliary HCO(3)(-) umbrella: A unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies[J]. Hepatology, 2010, 52(4): 1489-1496. DOI: 10.1002/hep.23810
[13]	MISZCZUK GS, BANALES JM, ZUCCHETTI AE, et al. Adaptive downregulation of Cl^-/HCO₃^- exchange activity in rat hepatocytes under experimental obstructive cholestasis[J]. PLoS One, 2019, 14(2): e0212215. DOI: 10.1371/journal.pone.0212215
[14]	HISAMOTO S, SHIMODA S, HARADA K, et al. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis[J]. J Autoimmun, 2016, 75: 150-160. DOI: 10.1016/j.jaut.2016.08.006
[15]	HOHENESTER S, WENNIGER LM, PAULUSMA CC, et al. A biliary HCO₃^- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes[J]. Hepatology, 2012, 55(1): 173-183. DOI: 10.1002/hep.24691
[16]	CHANG JC, GO S, DE WAART DR, et al. Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes[J]. Hepatology, 2016, 64(2): 522-534. DOI: 10.1002/hep.28550
[17]	SALAS JT, BANALES JM, SARVIDE S, et al. Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis[J]. Gastroenterology, 2008, 134(5): 1482-1493. DOI: 10.1053/j.gastro.2008.02.020
[18]	TRAUNER M, FICKERT P, BAGHDASARYAN A, et al. New insights into autoimmune cholangitis through animal models[J]. Dig Dis, 2010, 28(1): 99-104. DOI: 10.1159/000282072
[19]	CONCEPCION AR, SALAS JT, SÁEZ E, et al. CD8⁺T cells undergo activation and programmed death-1 repression in the liver of aged Ae2a, b-/- mice favoring autoimmune cholangitis[J]. Oncotarget, 2015, 6(30): 28588-28606. DOI: 10.18632/oncotarget.5665
[20]	CELAY J, LOZANO T, CONCEPCION AR, et al. Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms[J]. Haematologica, 2018, 103(6): 1065-1072. DOI: 10.3324/haematol.2017.175687
[21]	MA WT, CHEN DK. Immunological abnormalities in patients with primary biliary cholangitis[J]. Clin Sci (Lond), 2019, 133(6): 741-760. DOI: 10.1042/CS20181123
[22]	CONCEPCION AR, SALAS JT, SARVIDE S, et al. Anion exchanger 2 is critical for CD8(+) T cells to maintain pHi homeostasis and modulate immune responses[J]. Eur J Immunol, 2014, 44(5): 1341-1351. DOI: 10.1002/eji.201344218
[23]	ARENAS F, HERVÍAS I, SÁEZ E, et al. Promoter hypermethylation of the AE2/SLC4A2 gene in PBC[J]. JHEP Rep, 2019, 1(3): 145-153. DOI: 10.1016/j.jhepr.2019.05.006
[24]	XU LN, LI Y, PENG JY. microRNA and drug-induced liver injury[J]. Chin J Clin Pharmacol Ther, 2020, 25(7): 803-809. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL202007015.htm 许丽娜, 李月, 彭金咏. microRNA与药物性肝损伤[J]. 中国临床药理学与治疗学, 2020, 25(7): 803-809. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL202007015.htm
[25]	MO H, XU M. Research progress of microRNA-1290 in digestive system tumors[J]. China Med Herald, 2020, 17(29): 48-51. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202029014.htm 莫辉, 徐岷. microRNA-1290在消化系统肿瘤中的研究进展[J]. 中国医药导报, 2020, 17(29): 48-51. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202029014.htm
[26]	PADGETT KA, LAN RY, LEUNG PC, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression[J]. J Autoimmun, 2009, 32(3-4): 246-253. DOI: 10.1016/j.jaut.2009.02.022
[27]	SZABO G, BALA S. MicroRNAs in liver disease[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9): 542-552. DOI: 10.1038/nrgastro.2013.87
[28]	ERICE O, MUNOZ-GARRIDO P, VAQUERO J, et al. MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation[J]. Hepatology, 2018, 67(4): 1420-1440. DOI: 10.1002/hep.29533
[29]	BANALES JM, SÁEZ E, URIZ M, et al. Up-regulation of microRNA 506 leads to decreased Cl^-/HCO₃^- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis[J]. Hepatology, 2012, 56(2): 687-697. DOI: 10.1002/hep.25691
[30]	HONG JH, MUHAMMAD E, ZHENG C, et al. Essential role of carbonic anhydrase XⅡ in secretory gland fluid and HCO₃(-) secretion revealed by disease causing human mutation[J]. J Physiol, 2015, 593(24): 5299-5312. DOI: 10.1113/JP271378
[31]	HWANG S, SHIN DM, HONG JH. Drug repurposing as an antitumor agent: Disulfiram-mediated carbonic anhydrase 12 and anion exchanger 2 modulation to inhibit cancer cell migration[J]. Molecules, 2019, 24(18): 3409. DOI: 10.3390/molecules24183409
[32]	WANG W, REN X, CAI Y, et al. Rifampicin induces bicarbonate-rich choleresis in rats: Involvement of anion exchanger 2[J]. Dig Dis Sci, 2016, 61(1): 126-136. DOI: 10.1007/s10620-015-3850-2